Mylocar 60 mg Injection belongs to the group of proteasome inhibitors (anti-cancer medicines). It is used alone and in combination with other medications to treat people with multiple myeloma (a type of cancer of the bone marrow) who have already been treated with other medicines. Multiple myeloma, also known as myeloma, is a type of bone marrow cancer that affects several areas of the body, such as the spine, skull, pelvis, and ribs.

Mylocar 60 mg Injection contains Carfilzomib, which suppresses proteasomes that prevent protein breakdown in MM (multiple myeloma) cells. When proteasome function is stopped within the MM cell, a protein build-up occurs within the MM cell, which destroys the malignant cells.

Mylocar 60 mg Injection is administered in a hospital setting by a physician qualified by training and experience to administer cancer chemotherapeutic agents. Sometimes, you may experience common side effects, such as fatigue (feeling overtired), anaemia, nausea, thrombocytopenia (low platelet level), dyspnea (feeling short of breath), diarrhoea, and pyrexia (fever). Most of these side effects do not require medical attention and will resolve gradually over time. However, you are advised to talk to your doctor if any of these side effects persist or worsen.

Before taking the Mylocar 60 mg Injection, inform your doctor about all your allergic or hypersensitivity reactions to medicines or food. Mylocar 60 mg Injection can cause fetal harm when administered to a pregnant woman. It is critical not to become pregnant while undergoing therapy and for several months afterwards. Before beginning treatment, discuss effective contraception with your healthcare professional. Inform them immediately if you or your partner becomes pregnant while undergoing therapy. Breastfeeding is usually not advised during this treatment since it is unknown whether this medication passes into breast milk. Do not skip any laboratory checks because Thrombocytopenia, Hepatic Toxicity and Hepatic Failure may occur. If it happens, reduce or interrupt dosing as clinically indicated.

Carfilzomib, a proteasome inhibitor, is present in Mylocar 60 mg Injection. It suppresses proteasomes, preventing protein breakdown in MM (multiple myeloma) cells. When proteasome function is stopped within the MM cell, a protein build-up occurs within the MM cell, which destroys the malignant cells.

• Fatigue (feeling overtired)
• Anaemia (lack of blood)
• Nausea
• Thrombocytopenia (low platelet level)
• Dyspnea (feeling short of breath)
• Diarrhea
• Pyrexia (fever)
• Increased risk of infection
• Breathlessness and looking pale
• Bruising, bleeding gums or nosebleeds
• Low potassium levels in the blood
• Decreased appetite
• Difficulty sleeping (insomnia)
• Headache and dizziness
• Numbness or tingling in hands and feet
• High blood pressure
• Shortness of breath
• Cough
• Constipation
• Feeling sick or being sick
• Tummy (abdomen) Pain
• Joint, muscle or bone pain

Before taking Mylocar 60 mg Injection, inform your doctor about your medical history and other medications you are currently taking to rule out any potential negative effects. Avoid taking Mylocar 60 mg Injection if you are pregnant or breastfeeding or allergic to any component present in Mylocar 60 mg Injection. Both women and men using this Mylocar 60 mg Injection should use birth control to avoid pregnancy. Inform your doctor right away if you or your partner become pregnant during treatment with Mylocar 60 mg Injection. Inform your doctor if you have a history of heart failure and ischemia, Pulmonary Hypertension, Thrombocytopenia, low blood pressure or hepatic toxicity; your doctor will closely monitor and manage it. Carfilzomib injection may induce serious or life-threatening responses for up to 24 hours following administration. Before each dose of carfilzomib, you will be given specific drugs to assist in preventing a reaction. If you develop any of the following symptoms after your treatment, contact your doctor right away: fever, chills, joint or muscle pain, flushing or swelling of the face, swelling or tightening of the throat, vomiting, weakness, shortness of breath, disorientation or fainting, or chest tightness or pain.

Drug-Drug Interactions: Mylocar 60 mg Injection may interact with monoclonal antibodies (e.g. adalimumab), immunomodulatory medication (e.g. baricitinib, fingolimod), vaccines (e.g. BCG Vaccine, Denue vaccine), and antipsychotic medication (e.g. clozapine), and anabolic steroid hormone (methyltestosterone).

Drug-Food Interactions: Avoid the consumption of alcoholic beverages.

Drug-Disease Interactions: Mylocar 60 mg Injection may interact with various disease conditions, including tumour lysis syndrome (a condition that occurs when a large number of cancer cells die within a short period, releasing their contents into the blood), heart disease, pulmonary impairment, bleeding disorders, low or high blood pressure, renal or hepatic impairment and infections (bacterial/fungal/protozoal/viral).

• ADALIMUMAB
• BARICITINIB
• FINGOLIMOD
• BCG VACCINE
• DENGUE VACCINE
• CLOZAPINE
• METHYLTESTOSTERONE

• De-stress yourself by meditating, reading books, taking a warm bubble bath or listening to soothing music.
• Performing yoga may also help in improving both physical and mental health.
• Maintain a healthy weight by performing regular low-strain exercises and eating healthy food.
• Eat a healthy diet and exercise regularly to maintain proper weight.
• Include leafy vegetables, citrus fruits, fatty fish, berries, yoghurt, apples, peaches, cauliflower, cabbage, broccoli, beans, and herbs.
• Get optimal sleep; rest well.
• Avoid smoking and alcohol consumption.
• Avoid fast food, fried food, processed meats, refined carbs and added sugars.

• Pregnancy testing is recommended for females of reproductive potential prior to initiating treatment with Mylocar 60 mg Injection.
• Keep all appointments with your doctor and the laboratory. Your doctor will order laboratory tests before, during and after your treatment to check your body's response to Mylocar 60 mg Injection to see if your blood cells are affected by this drug.
• Do not donate sperm during treatment with Mylocar 60 mg Injection and for three months after your last dose.

Myeloma, also called multiple myeloma, is a cancer of the plasma cells. Plasma cells are white blood cells that make antibodies that protect us from infection. In myeloma, the cells grow too much, crowding out normal cells in the bone marrow that make red blood cells, platelets, and other white blood cells. Multiple myeloma, the most common type of plasma cell tumour, develops in the bone marrow and can spread throughout the body.